title: Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology.
abstract: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article.
  
  
  
  Systematic literature review with practice recommendations.
  
  
  
  Clinicians managing antithrombotic medications periprocedurally must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients undergoing invasive ocular anesthesia, cataract surgery, dermatologic procedures, transrectal ultrasound-guided prostate biopsy, spinal/epidural procedures, and carpal tunnel surgery should probably continue aspirin (Level B). Some stroke patients undergoing vitreoretinal surgery, EMG, transbronchial lung biopsy, colonoscopic polypectomy, upper endoscopy and biopsy/sphincterotomy, and abdominal ultrasound-guided biopsies should possibly continue aspirin (Level C). Stroke patients requiring warfarin should routinely continue it when undergoing dental procedures (Level A) and probably continue it for dermatologic procedures (Level B). Some patients undergoing EMG, prostate procedures, inguinal herniorrhaphy, and endothermal ablation of the great saphenous vein should possibly continue warfarin (Level C). Whereas neurologists should counsel that warfarin probably does not increase clinically important bleeding with ocular anesthesia (Level B), other ophthalmologic studies lack the statistical precision to make recommendations (Level U). Neurologists should counsel that warfarin might increase bleeding with colonoscopic polypectomy (Level C). There is insufficient evidence to support or refute periprocedural heparin bridging therapy to reduce thromboembolic events in chronically anticoagulated patients (Level U). Neurologists should counsel that bridging therapy is probably associated with increased bleeding risks as compared with warfarin cessation (Level B). The risk difference as compared with continuing warfarin is unknown (Level U).
authors.affiliation: Department of Neurology, University of Maryland School of Medicine, Baltimore, USA.
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Armstrong
authors.forename: Gary
authors.initials: G
authors.lastname: Gronseth
authors.forename: David C
authors.initials: DC
authors.lastname: Anderson
authors.forename: José
authors.initials: J
authors.lastname: Biller
authors.forename: Brett
authors.initials: B
authors.lastname: Cucchiara
authors.forename: Rima
authors.initials: R
authors.lastname: Dafer
authors.forename: Larry B
authors.initials: LB
authors.lastname: Goldstein
authors.forename: Michael
authors.initials: M
authors.lastname: Schneck
authors.forename: Steven R
authors.initials: SR
authors.lastname: Messé
mesh_terms: D002545:Brain Ischemia / Q000188:drug therapy*; D019317:Evidence-Based Medicine / Q000592:standards*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009462:Neurology / Q000592:standards*; D017410:Practice Guidelines as Topic; D012955:Societies, Medical / Q000592:standards*; D020521:Stroke / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents